Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Verrica Pharmaceuticals Inc (NQ: VRCA ) 0.9575 +0.1276 (+15.38%) Streaming Delayed Price Updated: 3:25 PM EST, Nov 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Verrica Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 Next > 12 Health Care Stocks Moving In Friday's Pre-Market Session December 15, 2023 Via Benzinga Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan December 15, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London November 10, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire 7 Analysts Have This to Say About Verrica Pharmaceuticals October 12, 2023 Via Benzinga Analyst Ratings for Verrica Pharmaceuticals August 10, 2023 Via Benzinga HC Wainwright & Co. Maintains Buy Rating for Verrica Pharmaceuticals: Here's What You Need To Know July 27, 2023 Via Benzinga Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results November 09, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Earnings Scheduled For November 9, 2023 November 09, 2023 Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. Via Benzinga Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 October 25, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 September 27, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference August 31, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises August 24, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum August 23, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting August 10, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results August 08, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting August 03, 2023 Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed July 26, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica's Ycanth Unlikely to Face Near-Term Competition, Analyst Upgrades Stock On FDA Approval July 25, 2023 Monday, the FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023 July 25, 2023 Via Benzinga $1M Bet On Verrica Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying July 25, 2023 Although US stocks closed higher on Monday, there were a few notable insider trades. Via Benzinga Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday July 24, 2023 The company's shares dropped because it will require financing to help launch its first marketed product. Via The Motley Fool Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 24, 2023 Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest. Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session July 24, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session July 24, 2023 Via Benzinga FDA Approves Verrica Pharma's Ycanth: First Treatment Of Molluscum Contagiosum Impacting 6M People In US July 24, 2023 The FDA approved Verrica Pharmaceuticals Inc's (NASDAQ: VRCA) Ycanth (cantharidin) topical solution for molluscum contagiosum (molluscum) in adult and pediatric patients Via Benzinga Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET July 24, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session July 21, 2023 Via Benzinga Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum July 21, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York May 31, 2023 From Verrica Pharmaceuticals Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Monday's After-Market Session May 29, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
